Clinical Trial Detail

NCT ID NCT03860207
Title Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

neuroblastoma

retinoblastoma

leiomyosarcoma

medulloblastoma

sarcoma

fibrosarcoma

spindle cell sarcoma

liposarcoma

melanoma

malignant fibrous histiocytoma

osteosarcoma

Therapies

Hu3F8-BsAb

Age Groups: senior child adult

No variant requirements are available.